Effective Jan. 1, 2018, newly approved biosimilar biologicals with a common reference product are no longer grouped into the same billing code. This change was finalized in the 2018 Medicare Physician Fee Schedule final rule. Q5102 Replaced with Two New Codes The April 2018 update to the Medicare Physician Fee Schedule Database (MPFSD) includes three […]
AAPC Knowledge Center
Click here for more sample CPC practice exam questions with Full Rationale Answers
Modifiers that identify the manufacturer of a biosimilar biological product are required on Part B claims. CMS updates assignment of modifiers to specific HCPCS codes quarterly. In situations where a HCPCS code is already associated with one or more modifiers and a new biosimilar biological product becomes available before its corresponding manufacturer’s modifier becomes effective, a not otherwise classified (NOC) code without a modifier may be used to bill for the new biosimilar product.
Below is the list of current biosimilar HCPCS Codes, the product(s) that are associated with each code and the corresponding required modifier that is used to identify the product. The table will be updated quarterly when new permanent HCPCS codes and modifiers are available for biosimilar products that appear on the ASP price file.
Q5101 Injection, Filgrastim (G-CSF), Biosimilar, 1 microgram Product Brand names – Zarxio Modifier – ZA – Novartis/Sandoz
Q5102 Injection, infliximab, biosimilar, 10 mg Product Brand names – Inflectra Modifier – ZB – Pfizer/Hospira
Q5102 Injection, infliximab, biosimilar, 10 mg Product Brand names – Renflexis Modifier – ZC –Merck/Samsung Bioepis
Note: The ZC modifier will become effective, that is, valid for claims submitted beginning October 1, 2017 and applies retroactively to dates of service on or after July 24, 2017.
For more information: https://go.usa.gov/xRQgQ
Laureen shows you her proprietary “Bubbling and Highlighting Technique”
Download your Free copy of my "Medical Coding From Home Ebook" at the top right corner of this page
Tag Archives: Biosimilar
Part B Biosimilar Biological Product Payment and Required Modifiers
Modifiers that identify the manufacturer of a biosimilar biological product are required on Part B claims. CMS updates assignment of modifiers to specific HCPCS codes quarterly. In situations where a HCPCS code is already associated with one or more modifiers and a new biosimilar biological product becomes available before its corresponding manufacturer’s modifier becomes effective, a not otherwise classified (NOC) code without a modifier may be used to bill for the new biosimilar product.
Below is the list of current biosimilar HCPCS Codes, the product(s) that are associated with each code and the corresponding required modifier that is used to identify the product. The table will be updated quarterly when new permanent HCPCS codes and modifiers are available for biosimilar products that appear on the ASP price file.
Q5101 Injection, Filgrastim (G-CSF), Biosimilar, 1 microgram Product Brand names – Zarxio Modifier – ZA – Novartis/Sandoz
Q5102 Injection, infliximab, biosimilar, 10 mg Product Brand names – Inflectra Modifier – ZB – Pfizer/Hospira
Q5102 Injection, infliximab, biosimilar, 10 mg Product Brand names – Renflexis Modifier – ZC –Merck/Samsung Bioepis
Note: The ZC modifier will become effective, that is, valid for claims submitted beginning October 1, 2017 and applies retroactively to dates of service on or after July 24, 2017.
For more information: https://go.usa.gov/xRQgQ